一項(xiàng)研究顯示使用他汀類藥物降低升高的膽固醇，能夠部分逆轉(zhuǎn)冠狀動(dòng)脈斑塊的形成。

這項(xiàng)研究在美國(guó)、加拿大、歐洲和澳洲的53個(gè)社區(qū)和III期護(hù)理中心進(jìn)行。總計(jì)507例患者接受了基線血管內(nèi)超聲檢查(IVUS)，該技術(shù)將一個(gè)微小超聲探頭插入冠狀動(dòng)脈中測(cè)量斑塊。在基線和治療24小時(shí)后測(cè)量了動(dòng)脈粥樣硬化的進(jìn)展。所有患者每日使用40 mg瑞舒伐他汀，該藥上市的商品名叫做Crestor。

研究結(jié)果顯示3種檢測(cè)方法都發(fā)現(xiàn)病變出現(xiàn)了減輕。平均基線低密度脂蛋白(LDL)膽固醇下降了53.2%，平均高密度脂蛋白(HDL)升高了14.7%。根據(jù)不同的指標(biāo)總體判斷，動(dòng)脈斑塊減少了6.8-9.1%。這種最大程度的膽固醇降低，曾經(jīng)在一項(xiàng)大型他汀類藥物試驗(yàn)中曾經(jīng)觀察到。這些結(jié)果在2006年3月Atlanta (GA, USA)舉行的美國(guó)心臟病學(xué)年度科學(xué)會(huì)議上進(jìn)行了報(bào)道。
 
Intensive Statin Therapy Reduces Coronary Plaque
 
A new study shows that very intensive cholesterol lowering with a statin drug can partially reverse the buildup of plaque in the coronary arteries.

The study was conducted at 53 community and tertiary care centers in the United States, Canada, Europe, and Australia. A total of 507 patients had baseline intravascular ultrasound (IVUS) examination, a technique in which a tiny ultrasound probe is inserted into the coronary arteries to measure plaque.

Atherosclerosis progression was assessed at baseline and at 24 months of treatment. All patients received 40 mg daily of rosuvastatin, a statin marketed under the brand name Crestor.

Results showed that regression occurred for all three pre-specified IVUS measures of disease burden. The mean baseline low density lipoprotein (LDL) cholesterol dropped by 53.2%, and mean high density lipoprotein (HDL) cholesterol increased by 14.7%. Arterial plaque overall was reduced by 6.8-9.1% for the various measures of disease burden. This is the largest reduction in cholesterol ever observed in a major statin outcome trial. The results were presented at the American College of Cardiology's annual scientific session, held during March 2006 in Atlanta (GA, USA).